The purpose of current investigation was to investigate in vivo and in vitro anti-diabetic potentials of aqueous extract of Alphonsea
sclerocarpa leaves against alloxan induced diabetes in albino rats. Two in vivo and one in vitro methods were performed for the
evaluation of aqueous extract for antidiabetic activity. For in-vivo evaluation, diabetes was induced in albino rats by administering a
single dose of alloxan. The study was designed to test the acute effect of aqueous extract of Alphonsea sclerocarpa (AEAS) to reduce
blood glucose in OGTT. The chronic study of 21 days was performed against diabetic rats and blood glucose was determined at 1st
,
7
th, 14th and 21st day. In chronic in vivo study, serum parameters insulin, urea, creatinine, total cholesterol, triglycerides, ALT and AST
were also estimated at 21st day to determine the effects of aqueous and aqueous extracts on complications of diabetes mellitus.
Glucose uptake by hemidiaphragm assay was performed to test the ability of extract to utilize glucose. In Oral Glucose Tolerance Test,
standard glibenclamide and aqueous extract (200mg/kg and 400mg/kg) treated animals have shown significant reduction in blood
glucose at 90 mins but at 120 mins. In chronic model the aqueous extract effectively reduced blood glucose levels (P<0.001) at 14th
and 21st day of study in therapeutic groups and effect was comparable to that of standard. The extract could also significantly
(P<0.001) reduce concentrations of SGOT, triglycerides, cholesterol and urea in serum and significantly (P<0.001) increased the insulin
level in blood which proves beneficial effects of the extract in diabetes. The change in concentrations of SGPT and urea were less
significant (P>0.01). The presence of extract in glucose uptake assay could significantly increase utilization of the glucose by rat
hemidiaphragm. The aqueous extract of Alphonsea sclerocarpa possess significant antidiabetic properties against alloxan induced
diabetic animals.